ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1

Targeted therapy using monoclonal antibodies conjugated to toxins is gaining space in the treatment of cancer. Here, we report the anti-tumor effect of a new antibody drug conjugate (ADC) delivering a HDAC inhibitor to ErbB2+ solid tumors. Trastuzumab was partially reduced with tris [2-carboxyethyl]...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Milazzo, Ferdinando Maria, Vesci, Loredana, Anastasi, Anna Maria, Chiapparino, Caterina, Rosi, Antonio, Giannini, Giuseppe, Taddei, Maurizio, Cini, Elena, Faltoni, Valentina, Petricci, Elena, Battistuzzi, Gianfranco, Salvini, Laura, Carollo, Valeria, De Santis, Rita
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6989603/
https://ncbi.nlm.nih.gov/pubmed/32039017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01534
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados